ANROAlto Neuroscience, Inc.
$24.00+304% 1Y
$24.00
$5.6252 weeks$36.63
Latest close: back above its 200-day averageOct 8, 2026what changed →
Price
+304%1YEnd-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for ANRO today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$842.3M
1 year+304%
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 27, 2026On August 26, 2026 (the “Effective Date” ), the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”) promoted Nicholas C. Smith, the Company’s Chief Financial Officer and Chief Business Officer, to the position of President and Chief Financial Officer, effective immediately.Director or officer change · Form 8-K
- Aug 12, 2026Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
- Jul 14, 2026On July 13, 2026, Alto Neuroscience, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the several underwriters set forth therein (collectively, the “Underwriters”), to issue and sell 3,776,436 shares of common stock of the …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry